The use of lipoprotein apheresis for the treatment of high-risk patients with elevated lipoprotein(a) and hypercholesterolemia

Abstract

Aim: To assess the safety and efficiency of H.E.L.P.-apheresis and cascade lipid-filtration in the treatment of severe lipid disorders in high-risk patients.

Methods: From 2016 to 2018 we observed 6 patients hyperLDLemia and high Lp(a)emia (> 60 mg/dL). The first group with H.E.L.P.-apheresis (n = 74 sessions) included 3 patients who underwent revascularization (coronary, femoral arteries). In the second group with cascade lipid-filtration (n = 92 sessions) - one patients underwent revascularization, two patients received drug therapy. Despite the lipid-lowering conventional therapy, no targeted low density lipoprotein (LDL) was obtained.

Results: The patients of the 1st group had threefold decrease of LDL, in patients of the 2nd group LDL decreased by 68%. At the same time, in both groups, we noted a decrease in Lp(a) after the procedure by 65%-68%. Despite a decrease in high density lipoprotein (by 22%-29%) after lipid apheresis procedures, there was a positive trend in apoB100/apoA index (a decrease of 33% after HELP-apheresis procedures and 60% after cascade lipid-filtration) and a decrease in atherogenic index (38% and 53%, respectively). The changes in hematological and haemostatic parameters remained within physiological intervals.

Conclusion: We noticed the successful application of lipid apheresis in patients with multifocal atherosclerosis and its complications.

Keywords

Lipid disorders / hyperLDLemia / high Lp(a)emia / multifocal atherosclerosis and its complications / atherogenic index / H.E.L.P.-apheresis / cascade lipid-filtration

References

[1] Sokolov AA,Kashtalap VV,Yezhov MV.Guidelines on the medical care organization to the patients with hereditary atherogenic lipid disorders in the Regions of Russia (Joint project of the national society for the research on atherosclerosis and non-profit partnership “The national council of experts on rare diseases”)..Bulletin Contempor Clin Med2017;10:83-8(in Russia)

[2] Townsend N,Scarborough P.Cardiovascular disease in Europe epidemiological update 2015..Eur Heart J2015;36:2696-705

[3] Bergheanu SC,Jukema JW.Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment..Neth Heart J2017;25:231-42 PMCID:PMC5355390

[4] Klose G,Marz W.Familial hypercholesterolemia: developments in diagnosis and treatment..Dtsch Arztebl Int2014;111:523-9 PMCID:PMC4148715

[5] Orsó E,Kilalić D.Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors..Atheroscler Suppl2009;10:74-8

[6] Sobenin IA,Grechko AV.Small dense and desialylated low density lipoprotein in diabetic patients..Vessel Plus2017;1:29-37

[7] Daniels SR.Lipid screening and cardiovascular health in childhood..Pediatrics2008;122:198-208

[8] Hohenstein B,Lansberg P,Mellwig KP.Rationale and design of MultiSELECt: a European multicenter study on the effect of Lipoprotein(a) elimination by lipoprotein apheresis on cardiovascular outcomes..Atheroscler Suppl2017;30:180-6

[9] Bos S,van Lennep JE.Latest developments in the treatment of lipoprotein(a)..Curr Opin Lipidol2014;25:452-60

[10] Lamon-Fava S,Marcovina SM.Lipoprotein(a) metabolism..Curr Opin Lipidol2014;25:189-93

[11] Pokrovsky SN,Safarova MS,Matchin YG.Specific Lp(a) apheresis: a tool to prove lipoprotein(a) atherogenicity..Atheroscler Suppl2017;30:166-73

[12] Stefanutti C.Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances..Curr Atheroscler Rep2015;17:465

[13] Abramyan MV.Possibilities of LDL-apheresis in the complex treatment of atherosclerosis..Creative Cardiology2007;1-2:208-19(in Russia)

[14] Makino H,Harada-Shiba M.LDL apheresis in Japan..Transfus Apher Sci2017;56:677-81

[15] Stefanutti C,Watts GF,Cossu M.Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs..J Clin Lipidol2017;11:858-71

[16] Waldmann E.Lipoprotein apheresis to treat elevated lipoprotein (a)..J Lipid Res2016;57:1751-7 PMCID:PMC5036372

[17] de Gennes JL,Maunand B,Laudat P.Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment..Bull Mem Soc Med Hop Paris1967;118:1377-402

[18] Thompson GR,Myant NB.Plasma exchange in the management of homozygous familial hypercholesterolaemia..Lancet1975;1:1208-11

[19] Thompson GR,Kilpatrick D,Raphael MJ.Assessment of longterm plasma exchange for familial hypercholesterolaaemia..Br Heart J1980;43:680-8 PMCID:PMC482769

[20] Briel M,You JJ,Akl EA.Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis..BMJ2009;338:b92 PMCID:PMC2645847

[21] Nenseter MS,Græsdal A,Halvorsen B.LDL-apheresis affects markers of endothelial function in patients with homozygous familial hypercholesterolemia..Thromb Res2012;130:823-5

[22] Derfler K,Sinzinger H.Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment..Wien Klin Wochenschr2015;127:655-63

[23] Julius U.History of lipidology and lipoprotein apheresis..Atheroscler Suppl2017;30:1-8

[24] Winters JL.Lipid apheresis, indications, and principles..J Clin Apher2011;26:269-75

[25] Julius U.Current role of lipoprotein apheresis in the treatment of high-risk patients..J Cardiovasc Dev Dis2018;5:27 PMCID:PMC6023350

[26] Kozik-Jaromin J,Heigl F,Ringel J.Safety aspects of lipidapheresis using DALI and MONET - multicenter observational study..Atheroscler Suppl2017;30:225-31

[27] Temizhan A,Cetin MS.Comparison of two lipid apheresis systems in patients with homozygous familial hypercholesterolemia: a single center 3-year experience..JACC2018;71:1780

[28] Klingel R,Fassbender C.Lipidfiltration-safe and effective methodology to perform lipid-apheresis..Transfus Apher Sci2004;30:245-54

[29] van Buuren F,Horstkotte D,Mellwig KP.HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures..Clin Res Cardiol Suppl2012;7:24-30 PMCID:PMC3374104

[30] Yarustovskiy MB,Pliysch MG,Nazarova EI.New medical technologies in cardiovascular surgery. Treatment of atherosclerosis and its complications using H.E.L.P.-apheresis method..Creative Cardiology2009;2:98-116(in Russia)

[31] Page MM,Hooper AJ,Burnett JR.Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children..Best Pract Res Clin Endocrinol Metab2014;28:387-403

[32] Schwartz J,Aqui N,Connelly-Smith L.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue..J Clin Apher2016;31:149-62

[33] Thompson GR,Saheb S,Barbir M.Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe..Curr Opin Lipidol2010;21:492-8

[34] Wang A,Gandra ShR,Kim L.Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia..J Am Heart Assoc2016;5:e003294 PMCID:PMC5015370

[35] Hovland A,Hardersen R,Mollnes TE.Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles..J Clin Apher2012;46:73-6

[36] Marcovina SM,Albers JJ.Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions..Clin Chem2003;49:1785-96

[37] Wang Y,Walli AK,Fraunberger P.Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins - reduction of circulating proinflammatory and procoagulatory markers..Atherosclerosis2004;175:145-50

[38] Moriarty PM,Oktona DC.Treating lipoprotein(a)- hyperproteinemia and progressive cardiovascular disease with lipid-apheresis in North America..JACC2018;71:1784

[39] Terai N,Haustein M,Pillunat LE.The effect of low-density lipoprotein apheresis on ocular microcirculation in patients with hypercholesterolemia: a pilot study..Br J Ophthalmol2011;95:401-4

[40] Sinzinger H,Derfler K.Pleiotropic effects of regular lipoprotein-apheresis..Atheroscler Suppl2017;30:122-27

[41] Hovland A,Mollnes TE.LDL apheresis and inflammation - implications for atherosclerosis..Scand J Immunol2012;76:229-36

[42] Kopprasch S,Bergmann S,Julius U.Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters - a comparison of two different apheresis techniques..Atheroscler Suppl2015;18:80-4

[43] Hibino S,Tsuda H.Effect of double filtration plasmapheresis (DFPP) in male patients with borderline hyper-LDL-cholesterolemia: lipid removal and inflammation suppreesion..Anti-Aging Medicine2009;6:32-40

[44] Hovland A,Nielsen EW,Lappegård KT.Hematologic and hemostatic changes induced by different columns during LDL apheresis..J Clin Apher2010;25:294-300

[45] Rogova LN,Pankova GV.Pathogenetic substantiation of the interpretation of the results of hematological analysis of blood..Bulletin of Medical Internet Conferences2016;6:1568-72(in Russia)

[46] Thompson GR,Davies D,Gesinde M.Efficacy criteria and cholesterol targets for LDL apheresis..Atherosclerosis2010;208:317-21

[47] Blaha M,Cap J,Mašín V.WAA apheresis registry in the Czech Republic: two centers experience..Transfus Apher Sci2009;41:27-31

[48] Borberg H.26 years of LDL - apheresis: a review of experience..Transfus Apher Sci2009;41:49-59

[49] Henriksson MM,Witt V,Leitner G.Adverse events in apheresis: an update of the WAA registry data..Transfus Apher Sci2016;54:2-15

[50] Stegmayr B,Newman E,Derfler K.Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry..Transfus Apher Sci2017;56:71-4

[51] Heigl F,Lotz N,Pflederer T.Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany..Atheroscler Suppl2015;18:154-62

[52] Geiss HC,Donner MG.Low-density lipoprotein apheresis by membrane differential filtration. The Scientific World Journal (cascade filtration)..Ther Apher Dial1993;3:199-202